- Patent Title: Antibodies against vascular endothelial growth factor receptor 2 (VEGFR2), encoding nucleic acid molecules and methods for treating an angiogenesis-related disease
-
Application No.: US15780046Application Date: 2016-11-25
-
Publication No.: US10465008B2Publication Date: 2019-11-05
- Inventor: Jong Seo Lee , Kyu Tae Kim , Bong Kook Ko , Ki Hyun Kim , Hyun Jong Lee
- Applicant: ABCLON INC.
- Applicant Address: KR Seoul
- Assignee: ABCLON INC.
- Current Assignee: ABCLON INC.
- Current Assignee Address: KR Seoul
- Agency: Maier & Maier, PLLC
- Priority: KR10-2015-0168859 20151130
- International Application: PCT/KR2016/013735 WO 20161125
- International Announcement: WO2017/095088 WO 20170608
- Main IPC: C07K16/28
- IPC: C07K16/28 ; G01N33/577 ; A61P37/06 ; A61P35/00
Abstract:
A novel antibody against VEGFR2 for use in the prevention or treatment of macular degeneration and cancer, which are angiogenesis-related diseases. The antibody of the present invention is an antibody which specifically binds to VEGFR2 which is overexpressed in vascular endothelial cells. The antibody of the present invention has very low homology compared to the CDR sequences of conventional VEGFR2 target antibodies, and thus is unique in its sequence. Since the antibody of the present invention, when treated alone, has the ability to inhibit vascular endothelial cell growth equivalent to that of ramucirumab which is conventionally used, it is very effective to prevent or treat angiogenesis-related diseases.
Public/Granted literature
- US20190241666A1 ANTIBODY SPECIFICALLY BINDING TO VEGFR2 Public/Granted day:2019-08-08
Information query
